Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
M&A / Property

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

By The Northwire Desk — AI Analysis Mar 30, 2026 · 07:50 QNTM · 6.57 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • Quantum BioPharma entered a binding Letter of Intent with contract research organization Allucent to conduct the planned Phase 2 trial of its lead asset Lucid‑MS for multiple sclerosis.
  • The partnership is intended to accelerate trial start‑up, site selection, patient recruitment, data management and regulatory support, with the trial targeted to begin in Q2 2026 pending approvals.
  • Lucid‑MS represents a first‑in‑class neuroprotective approach that targets demyelination, differentiating it from existing immune‑modulating MS therapies.

Key Details

  • Letter of Intent (LOI): Binding agreement with Allucent to provide comprehensive CRO services for the Phase 2 study of Lucid‑MS.
  • Trial Timeline: Expected initiation in the second quarter of 2026, subject to regulatory approvals and finalization of trial design.
  • Scope of Services:
  • Study start‑up – regulatory submissions, ethics approvals, accelerated initiation.
  • Site selection & management – global network coordination for optimal patient access.
  • Patient recruitment – enrollment strategy and execution for efficient completion.
  • Data management – collection, analysis, reporting to ensure rigorous data integrity.
  • Regulatory support – agency interactions and compliance to streamline development pathway.
  • Therapeutic Rationale: Lucid‑MS is a new chemical entity designed to provide neuroprotection by inhibiting demyelination, addressing disease progression rather than solely modulating the immune system.
  • Quotes:
  • “Lucid‑MS is a First‑in‑Class…designed to provide neuroprotection through the inhibition of demyelination…” – Andrzej Chruscinski, VP Scientific & Clinical Affairs.
  • “We are pleased to engage Allucent…their therapeutic expertise and global operational capabilities are expected to support the efficient execution of our Phase 2 trial.” – Zeeshan Saeed, CEO.
  • Market Context: MS affects ~2.8 million people worldwide; the global MS therapeutic market is projected to exceed $38 billion by 2030. Lucid‑MS aims to capture share in the emerging neuroprotective segment.

Notable Quotes

  • “We’re proud to partner with Quantum BioPharma in advancing their neuro‑degenerative clinical program in multiple sclerosis.” – Paula Brown Stafford, CEO of Allucent.
Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other